Journal article
The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable
L Chin-Lenn, RH De Boer, E Segelov, GM Marx, TM Hughes, NJ McCarthy, SC White, SS Foo, JJ Rutovitz, S Della-Fiorentina, R Jennens, YC Antill, D Tsoi, MF Cronk, JM Lombard, BE Kiely, JH Chirgwin, A Gorelik, GB Mann
Asia Pacific Journal of Clinical Oncology | WILEY | Published : 2018
DOI: 10.1111/ajco.13075
Abstract
Objectives: Industry-supported decision impact studies demonstrate that Oncotype Dx (ODX) changes treatment recommendations (TR) in 24–40% of hormone receptor+/HER2− patients. ODX is not reimbursed by third-party payers in Australia, potentially resulting in more selective use. We sought to evaluate the impact of self-funded ODX on TRs. Methods: Data collected included demographics, tumor characteristics, indication for ODX and pre- and post-recurrence score (RS) TR. Primary endpoint was frequency of TR change and associations with TR change were sought. Results: Eighteen physicians contributed 382 patients (median age 54). A total of 232 (61%) of tumors were T1 and were grade 1, 2 and 3 in ..
View full abstract